Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MYNZ diagnostics products are impressive...
*Provide multiple shots on revenue-generating goals
*ColoAlert colorectal cancer diagnostic test, which targets a massive market opportunity.
*Another value driver in PancAlert; its pancreatic cancer detection test, which also reached multiple preclinical milestones.
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26
Great article... nice close yesterday, looking for a continuation today.
Biotech Stocks could be recession proof as bond market plunges (MYNZ, RVNC, AXSM, ABBV) - CinCor Pharma (NASDAQ:CINC), Axsome Therapeutics (NASDAQ:AXSM) - Benzinga
https://www.benzinga.com/pressreleases/22/09/ab29002308/biotech-stocks-could-be-recession-proof-as-bond-market-plunges-mynz-rvnc-axsm-abbv
$MYNZ new high of the day, UP almost 8% at $7.40, on News today!
News September 26, 2022
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics ($MYNZ) https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26
$MYNZ new high of the day on the ASK, up nearly 3% as we start Power Hour!
$MYNZ looking good as lunchtime edges to a close... trading just under 25% of its 10-day average volume, BUT UP almost 2% @$7.
Article September 26, 2022
There’s No Doubt About It, Early Detection Saves Lives Mainz Biomed N.V. (NASDAQ:MYNZ)
https://investorbrandmedia.com/mynz-stock-alert/
7.10 ready to go, thin here to a new high of day!
$MYNZ
Holding green
$MYNZ BID now higher than the current price...
mRNA Biomarkers - The Company Recently Acquired Exclusive Rights To Novel mRNA BBiomarkers
Wow huge news to start the week! Sep 26, 2022 (AB Digital via COMTEX) -- Mainz Biomed (NASDAQ: MYNZ) stock may present a value investment opportunity too good to ignore. In fact, a move higher is the likely path of least resistance for this thinly traded molecular genetics diagnostics company. They have a well-fortified balance sheet, best-in-class early cancer detection tests, and a management team that's part of a Who's Who list in biotech management fueling that proposition.
But there's more to validate that case. Like most smallcap biotechs in this turbulent market, MYNZ stock has disconnected from its fundamentals and pushed lower despite reaching milestones. These include successfully raising $25.8 million (gross) in new capital, having less than $1 million in long-term debt, and generating revenues from an early cancer detection diagnostics portfolio.
Those diagnostics products, their primary value drivers, are impressive. They also provide multiple shots on revenue-generating goals. And not just from its flagship ColoAlert colorectal cancer diagnostic test, which targets a massive market opportunity. They have another value driver in PancAlert; its pancreatic cancer detection test. It also reached multiple preclinical milestones supporting its development as a first-in-class diagnostic for this deadly cancer indication.
Thus, positioned better than at any time in history to accelerate growth, with cash and products supporting its mission, MYNZ is an investment consideration based on merit, not hype. $MYNZ
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics $MYNZ
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26?reflink=mw_share_twitter
$MYNZ News September 26, 2022
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics ($MYNZ) https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26
Premarket looked pretty good!
Might be an opportunity to get some cheaper shares this morning. These prices are a good deal in the long term.
Super thin ask, this can move big.
$MYNZ
Nice and green today in pre market
$MYNZ news alert: The Biotech Stocks that could be recession proof as bond market plunges https://www.marketwatch.com/press-release/biotech-stocks-could-be-recession-proof-as-bond-market-plunges-mynz-rvnc-axsm-abbv-2022-09-26?reflink=mw_share_twitter
$MYNZ 127% year-over-year increase in ColoAlert revenue
Should see a nice move from these levels!
$MYNZ
$MYNZ - Executed a $25.8 million (gross) public follow-on offering.
https://finance.yahoo.com/news/mainz-biomed-reports-first-half-070100420.html
$MYNZ looking better as we head into the last 30 minutes of the day...
Great point... The stock market, crypto market and housing market are getting crushed. But when blood in the streets.
Great opportunity here with $MYNZ
$MYNZ - A high-profile partnerships with leading laboratory Labor MVZ Dr. Stein + Kollegen, commonly referred to as “Laboratory Mönchengladbach” (February), one of the largest diagnostics laboratories in Germany, servicing over 2,500 physicians, processing over five million samples annually and screening approximately 1,000 patients per week specifically for CRC.
https://finance.yahoo.com/news/mainz-biomed-reports-first-half-070100420.html
Chart is fubar....I will wait for a 600% haircut never catch a falling knife
It’s market conditions that every stock is dealing with right now. Smart money is DCAing. Anyone with cash will make huge gains when the market turns back positive
$MNYZ trading 35% over its 10-day average volume...ColoAlert, (NASDAQ: $MYNZ), has a specificity of 92% while ColoGuard, (NASDAQ: $EXAS), is at 87%!
*ColoAlert utilizes proprietary methods to analyze the cell DNA for specific tumor markers.
$MYNZ nice bounce off the low this morning, with BID and ASK spread tightened
Fell below support..Fell below 50ma 100ma 200ma to 52 week lows..
ITS A FALLING KNIFE...ITS GOING BELOW at least another 600% down...Wouldn't touch this one ITS done...
ColoAlert Holds Potential as a Blockbuster Early Detection Test for Colorectal Cancer and Could Turn Mainz Biomed (NASDAQ: $MYNZ) into One of the Biggest GROUND-FLOOR Success Stories on Wall Street!
Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board
https://finance.yahoo.com/news/mainz-biomed-appoints-dr-douglas-070100627.html
$MYNZ - Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer.
https://finance.yahoo.com/news/mainz-biomed-reports-first-half-070100420.html
Nice rebound off the low of the day... $MYNZ
$MYNZ a $3.7 Billion Market Opportunity https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$MYNZ holding steady, trading over 40% of its 10-day average volume, down slightly...
ColoAlert, Mainz Biomed's flagship product, combines the advantages of a colonoscopy and an occult blood test.
https://www.l3opptrk.com/3J67C1/3T3PPKJ/
$MYNZ trading nearly 2x over its average volume as we approach the last 30 minutes of the day... UP almost 16%!
$MYNZ another strong close coming!
$MYNZ trading 75% over its 10-day average volume as Power Hour approaches...but UP almost 15%. Looking great!
Good morning $MYNZ. Nice start to the day, UP almost 4%!
$MYNZ trading just under 45% of its 10-day average volume with 2.5 hours left in the day... Holding steady.
Nice move by $MYNZ!
As an integral part of her role, Ms. Edwards will manage the design and logistical operations of the Company’s multifaceted clinical trials - to include subjects in the US and EU - which support key stages of the FDA submission process for ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). She will also develop and liaise closely with Key Opinion Leaders responsible for carrying out, or contributing to, both the European and US clinical studies and supporting related publications.
Mainz Biomed recently announced a partnership with Dante Labs for the commercialization of ColoAlert in Europe and the United Arab Emirates (UAE).
MYNZ
$MYNZ News Out! Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission https://finance.yahoo.com/news/mainz-biomed-appoints-vice-president-070100301.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
Followers
|
8
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
199
|
Created
|
11/05/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |